Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review

Legacy of Evidence-Based Health Communication

General health and science communication has long emphasized the importance of evidence-based understanding of medical interventions, including the balance between therapeutic benefits and potential risks. In the context of oncology, public health messaging has historically focused on treatment efficacy and patient outcomes, often framed within broad educational initiatives. This legacy provides a foundation for examining specific pharmaceutical agents and their associated health considerations. Transitioning from this general health perspective, attention now turns to occupational exposure scenarios. In mass production environments, workers may encounter pharmaceutical compounds during manufacturing, handling, or quality control processes. Avelumab, a monoclonal antibody used in cancer therapy, represents one such agent where occupational exposure warrants careful evaluation. The shift from patient-centered clinical contexts to workplace safety concerns requires a focused review of available evidence regarding potential health effects. Specifically, the relationship between avelumab exposure and Merkel cell carcinoma risk emerges as a critical area for occupational health assessment. This pivot acknowledges that while clinical applications prioritize therapeutic outcomes, industrial settings demand rigorous examination of unintended exposure consequences. The following analysis will explore the clinical evidence base relevant to this occupational health question, maintaining the same commitment to evidence-based reasoning that characterizes general health science communication.

Bridge from General Health to Occupational Exposure

Building on the legacy of evidence-based communication, this section explicitly transitions from general health principles to the specific context of occupational exposure to avelumab. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). In occupational settings, workers may be exposed to avelumab during manufacturing or handling, raising questions about potential health effects. The following sections examine the clinical evidence regarding avelumab's role in MCC causation and its risk profile.

Clinical Evidence on Avelumab and Merkel Cell Carcinoma

Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab, as an anti-PD-L1 inhibitor, is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; this hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab can trigger immune-related adverse events, these may be manageable without discontinuation of therapy. For patients who become refractory to avelumab, treatment options are limited. In a multicenter study of the prospective skin cancer registry ADOREG, patients with avelumab-refractory MCC were treated with combined ipilimumab and nivolumab (https://pubmed.ncbi.nlm.nih.gov/36450381/). In a separate retrospective study, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). These findings suggest that alternative immune checkpoint inhibitor combinations may provide benefit after avelumab failure.

Causation and Risk Context

From a causation perspective, the timeline between avelumab exposure and documented harm is relevant. Immune-related adverse events, such as the reactivation of sarcoidosis leading to hypercalcaemia, can occur during treatment with avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). The development of avelumab-refractory disease is also a documented outcome, with approximately half of patients progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The clinical presentation of MCC itself includes high rates of recurrence and mortality, and the disease is aggressive regardless of treatment (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding the adequacy of warnings, the approved labeling for avelumab includes its indication for metastatic MCC and its mechanism as a PD-L1 inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune-related adverse events are a known class effect of checkpoint inhibitors, and the reported case of sarcoidosis reactivation highlights a specific risk (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, the evidence does not indicate that avelumab causes MCC; rather, it is used to treat MCC. The risk narrative for affected patients centers on the potential for immune-related adverse events and the possibility of disease progression despite treatment. For patients who experience avelumab-refractory disease, alternative therapies such as ipilimumab plus nivolumab may offer benefit (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab is an effective treatment for metastatic MCC, with a response rate of approximately one-third in chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). It carries a risk of immune-related adverse events, including rare events such as sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, combination immunotherapy may be a viable option (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The evidence supports that avelumab is a treatment for MCC, not a cause of the disease, and that its risks are consistent with those of the immune checkpoint inhibitor class.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not indicate that avelumab causes Merkel cell carcinoma. Avelumab is a treatment for metastatic Merkel cell carcinoma, not a cause of the disease. It is an immune checkpoint inhibitor that targets PD-L1 and has been shown to produce objective responses in approximately one-third of chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks associated with avelumab exposure?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, including rare events such as sarcoidosis reactivation leading to hypercalcaemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, approximately 50% of patients with advanced Merkel cell carcinoma may progress on avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). These risks are consistent with the class of immune checkpoint inhibitors.

What treatment options exist for patients who progress on avelumab?

For patients with avelumab-refractory Merkel cell carcinoma, alternative immune checkpoint inhibitor combinations such as ipilimumab plus nivolumab may provide benefit. Studies have shown responses in some patients after avelumab failure (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.